Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pazufloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 6/20 | 0.63 |
| ▸ | TOP2B known ✓ | Q02880 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | ALB | P02768 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TUBB | P07437 | 1/20 | 0.62 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.62 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.62 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.62 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.62 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.62 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.62 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazufloxacin SCHEMBL8386358 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL21074686 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL29381001 | 1.00 | KDM4E (1.00) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL9873706 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28659469 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL9872951 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28064894 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL28087423 | 0.99 | KDM4E (0.98) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL29380457 | 0.95 | KDM4E (0.91) | KDM4EKMT2AAADATTOP2ATOP2B | |
| Pazufloxacin SCHEMBL4442183 | 0.95 | KDM4E (0.91) | KDM4EKMT2AAADATTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5162 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4603146-A2 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | Helperby Therapeutics Limited (GB) | 2025-08-20 | — | — | EP | claimed |
| EP-4028022-B1 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | HELPERBY THERAPEUTICS LTD (GB) | 2025-07-09 | — | — | EP | claimed |
| EP-4554627-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-21 | — | — | EP | claimed |
| EP-4554939-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2025-05-21 | — | — | EP | claimed |
| CN-119985774-A | Method for detecting photodegradation impurity in pazufloxacin mesylate sodium chloride injection | 安徽恒星制药有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20250144088-A1 | INHALABLE FORMULATION FOR USE IN THE TREATMENT OF BACTERIAL LUNG INFECTIONS | Solmic Biotech GmbH (DE) | 2025-05-08 | — | — | US | claimed |
| CN-119915935-A | Synchronous detection method for 42 antibiotics in river mouth multi-environment medium | 华东师范大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119894504-A | Inhalable formulation for treating bacterial infections in the lungs | 索米克生物技术有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2001054691-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX, S.A. (FR) | 2001-08-02 | — | — | WO | claimed |
| WO-2001045679-A2 | USE OF CHEMOTHERAPEUTIC AGENTS FOR TOPICAL TREATMENT | SCHULZ HANS HERRMANN (DE) | 2001-06-28 | — | — | WO | claimed |
| EP-1085891-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-1999064054-A9 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999064054-A1 | MULTIBINDING INHIBITORS OF TOPOISOMERASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-4990508-A | Reduced side effects | TOYAMA CHEMICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | claimed |